CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 40-424

CHEMISTRY REVIEW(S)

- 1. CHEMISTRY REVIEW NO: 2/3
- 2. ANDA: 40-424
- 3. NAME AND ADDRESS OF APPLICANT:

Mylan Pharmaceuticals Inc.

Attention: Frank Sisto 781 Chestnut Ridge Road

P.O. Box 4310

Morgantown, WV 26504-4310 Telephone: 304-599-2595 Facsimile: 304-285-6407

- 4. LEGAL BASIS for ANDA SUBMISSION: See Chemistry Review #1
- 5. SUPPLEMENT(s): N/A
- 6. PROPRIETARY NAME: N/A
- 7. NONPROPRIETARY NAME: Spironolactone Tablets USP
- 8. SUPPLEMENT(s) PROVIDE(s) FOR: N/A
- 9. AMENDMENTS AND OTHER DATES:

Original Submission: 11/13/00

Amendment: 4/27/01 Amendment: 5/10/01

Telephone Amendment: 6/25/01

Amendment: 6/27/01

Telephone Amendment: 7/27/01

- 10. PHARMACOLOGICAL CATEGORY: Diuretic
- 11. OTC/R_x : R_x
- 12. RELATED IND/NDA/DMF(s): See DMF Checklist
- 13. DOSAGE FORM: Coated Tablets
- 14. STRENGTH: 25 mg, 50 mg, and 100 mg
- 15. CHEMICAL NAMES AND STRUCTURE:

Pregn-4-ene-21-carboxylic acid; 7-(acetylthio)-17-hydroxy-3-oxo-, γ -lactone, $(7\alpha,17\alpha)$ -; $C_{24}H_{32}O_4S$; MW = 416.59. CAS #52-01-7; Diuretic; Aldosterone Antagonist.

- 16. RECORDS AND REPORTS: N/A
- 17. COMMENTS: This reviewer feels that some of the data used to support this ANDA may be suspect (see stability section of this review).
- 18. CONCLUSIONS AND RECOMMENDATIONS: Approvable
- 19. REVIEWER: ARAW DATE COMPLETED: 6/07/01

Revised (Telephone Amendments): 8/01/01

cc: :

Endorsements:

MI : Run e/14/01

€.

Contain Trade Secret,

Commercial/Confidential

Information and are not
releasable.

Ven Per /

6/7/6/